Overactive NF‑κB signaling in myeloproliferative neoplasms
Official title: Dysregulated NFkB Pathway Signaling In Myeloproliferative Neoplasms
Funded at Washington University · NIH-11238087 · Data updated 2026-11-12
This project looks at whether blocking an overactive cell-signaling pathway called NF‑κB can slow or stop disease progression in people with myeloproliferative neoplasms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | December 11, 2017 |
| Project end | November 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $606,416 |
| NIH project number | 5R01HL134952-08 |
| Project ID | NIH-11238087 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with a myeloproliferative neoplasm (for example, polycythemia vera, essential thrombocythemia, or myelofibrosis) who can provide samples or participate at a study site.
✕Less likely to help
People without MPNs or those seeking immediate changes to their personal medical treatment are unlikely to benefit directly from this research at this time.
What this research studies
Researchers will study blood and bone marrow samples from people with MPNs and run complementary experiments in mouse models to understand how NF‑κB signaling drives disease. The team will measure NF‑κB activity in patient cells and compare those findings to what they see in mice. They will test drugs or genetic approaches that reduce NF‑κB activity in models to see if disease features, like bone marrow fibrosis and abnormal blood counts, improve. Results could point to new treatment strategies or support future clinical trials for people with MPNs.
Why it matters
Potential benefit: If successful, this work could lead to therapies that slow or stop disease progression and reduce symptoms for people with MPNs.
How similar studies have gone: Prior lab and animal studies suggest that blocking NF‑κB can reduce disease features, but proven benefit in human MPN patients is still limited.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Oh, Stephen — Washington University
- Study coordinator: Oh, Stephen
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.